Table 1. Patient and treatment characteristics.
TN: trigeminal neuralgia; CNV1: cranial verve V–ophthalmic branch; CNV2: cranial nerve V–maxillary branch; CNV3: cranial nerve V–mandibular branch; VAS: visual analogue pain scale; BNI: Barrow Neurological Institute Pain scale; RF: radiofrequency; PMC: percutaneous microballoon compression; MVD: microvascular decompression; NSAIDs: nonsteroidal anti-inflammatory drugs
Refused: patients refused other types of invasive treatments.
| Patient | Age | Sex | Duration of pain (months) | Duration of crisis (weeks) | Primary or secondary TN | Type of medications used | Type of previous treatments | Affected side | Affected branch | Thalamotomy | Dose to nerve and thalamus | VAS prior to treatment | BNI prior to treatment |
| 1 | 60 | F | 13 | 8.5 | Primary | NSAIDs, neuromodulators | RF PMC | Right | CNV1, CNV2, CNV3 | Left | 90/140 Gy | 10 | 5 |
| 2 | 57 | F | 72 | 10.5 | Primary | Neuromodulators | MVD | Left | CN2, CNV3 | Right | 90/140 Gy | 10 | 5 |
| 3 | 78 | F | 48 | 12 | Primary | NSAIDs, neuromodulators | Refused | Right | CNV1, CNV2, CNV3 | Left | 90/140 Gy | 10 | 5 |
| 4 | 85 | M | 19 | 5.5 | Primary | Neuromodulators, opioids | Refused | Right | CNV2, CNV3 | Left | 90/140 Gy | 10 | 5 |
| 5 | 41 | M | 144 | 8.5 | Primary | NSAIDs, neuromodulators | Refused | Right | CNV1, CNV2, CNV3 | Left | 90/140 Gy | 10 | 5 |
| 6 | 60 | F | 36 | 11 | Primary | Neuromodulators | RF PMC | Right | CNV1, CNV2, CNV3 | Left | 90/140 Gy | 10 | 5 |
| 7 | 69 | F | 120 | 16 | Secondary | Neuromodulators | RF | Right | CNV1, CNV2, | Left | 90/140 Gy | 10 | 5 |
| 8 | 56 | F | 144 | 20 | Primary | NSAIDs, neuromodulators | RF PMC | Right | CNV1, CNV2, CNV3 | Left | 80/120 Gy | 10 | 5 |